Algernon Pharmaceuticals Inc (AGNPF)

[markna]

The big question here is can they actually raise $ to actually do a study. As I mentioned earlier, they press released $1M minimum raise needed as part of Nash acquisition, yet only could only do $500k and that was last summer so obviously having troubles raising the $. The next risk is they don’t raise enough and take short cuts in trial setups would assume they would need at least 40 patients for phase 2, assuming minimum 3 months treatment would likely run $100,000 per patient thus $3M. If company tells you it can be done for a lot cheaper, I’d be worried about shortcuts that risk results . . .